DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop WB-06-05
Baltimore, Maryland 21244-1850

CENTER FOR MEDICARE

DATE: November 25, 2025

TO: Medicare Advantage & Prescription Drug Plan Sponsors

FROM: Lara Strawbridge, Acting Director
Medicare Drug Rebate and Negotiations Group

SUBJECT: Removal of Entresto, Stelara, and Xarelto from the Selected Drug List Effective January 1, 2027

In accordance with section 1192(c)(1) of the Social Security Act (the Act) and section 70 of the Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026 ("Revised Guidance"), the following selected drugs will cease to be selected drugs and the agreed-upon maximum fair prices will cease to apply on January 1, 2027:

- Entresto
- Stelara
- Xarelto

In accordance with section 70 of the Revised Guidance, CMS determined that, for each of these selected drugs, the totality of circumstances reveals that at least one generic drug approved under 505(j) of the FD&C Act that identifies the selected drug as its reference-listed drug or biosimilar biological product licensed under 351(k) of the PHS Act that identifies the selected drug as its reference product, as applicable, is being bona fide marketed pursuant to such approval or licensure.

In accordance with section 1192(c)(1) of the Act and section 70 of the Revised Guidance, because CMS made this determination after August 1, 2024, and before April 1, 2026, these selected drugs will remain as selected drugs through 2026 and the agreed-upon maximum fair prices will apply through December 31, 2026. These selected drugs will cease to be selected drugs and the agreed-upon maximum fair prices will cease to apply on January 1, 2027.

For questions, please contact IRARebateandNegotiation@cms.hhs.gov.